The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112401 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xiangyu Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China; School of Medicine, Southeast University, …. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Jumonji Domain-Containing Histone Demethylases, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: This study aimed to investigate the role of JMJD2A in radiotherapy tolerance of esophageal squamous cell carcinoma (ESCC). METHODS: The levels of H3K9me3 modification were analyzed in anti-PD-1 therapy non-responder or responder patients, and the expression differences of H3K9me3-related modifying enzymes were assessed in TCGA-ESCC and ICGC cohorts. Subsequently, JMJD2A was knocked down in ESCC cells using CRISPR-Cas9 or lentivirus-mediated shRNA, and changes in malignant behavior of ESCC cells were observed. RNA-seq, ATAC-seq, and ChIP-seq analyses were then conducted to investigate the genes and downstream signaling pathways regulated by JMJD2A, and functional validation experiments were performed to analyze the role of downstream regulated genes and pathways in ESCC malignant behavior and immune evasion. RESULTS: JMJD2A was significantly overexpressed in ESCC and anti-PD-1 therapy non-responders. Knockdown or deletion of JMJD2A significantly promoted the malignant behavior and immune evasion of ESCC. JMJD2A facilitated the structural changes in chromatin and promoted the binding of SMARCA4 to super-enhancers, thereby inducing the expression of GPX4. This resulted in the inhibition of radiation-induced DNA damage and cell ferroptosis, ultimately promoting the malignant behavior and immune evasion of ESCC cells. CONCLUSION: JMJD2A plays an indispensable role in the malignant behavior and immune evasion of ESCC. It regulates the binding of SMARCA4 to super-enhancers and affects the chromatin's epigenetic landscape, thereby promoting the expression of GPX4 and attenuating iron-mediated cell death caused by radiotherapy. Consequently, it triggers the malignant behavior and immune evasion of ESCC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China; School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Internal Medicine of Traditional Chinese Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Pathology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
- Department of Medical Oncology, Luhe People's Hospital of Nanjing, Nanjing 210000, China.
- Department of Ultrasound, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China. Electronic address: shijinjun_0@sohu.com.
Zitieren
APA
Su, X., Ding, X., Ding, C., Wang, G., Fu, C., Liu, F., Shi, J., & He, W. (2024). The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112401
Vancouver
Su X, Ding X, Ding C, Wang G, Fu C, Liu F, et al. The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112401
BibTeX
@article{Su2024,
author = {Su, Xiangyu and Ding, Xu and Ding, Chenxi and Wang, Guoqing and Fu, Chenchun and Liu, Fei and Shi, Jinjun and He, Wei},
title = {The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112401}
}
EUVIMED